Testosterone and Growth Hormone for Bone Loss in Men

Completed · Phase 2

Conditions studied: Hypopituitarism, Hypogonadism, Growth Hormone Deficiency

In brief

Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.

Key facts

Study ID

NCT00080483

Run by

University of Pennsylvania

People needed

35

Starts

2004-03-01

Expected to finish

2010-09-01

Last updated by the study team

2014-06-13

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Documented hypothalamic or pituitary hormone deficiency
• Testosterone deficiency, defined as total serum testosterone less than 250 ng/dL at two 8 AM readings
• Growth hormone deficiency, defined by either of the following:
• For subjects who have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
• For subjects who do not have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
• Duration of testosterone and growth hormone deficiencies of two years or more
• Replacement of cortisol and/or thyroxine deficiencies
• Able to give informed consent

You may not qualify if…

• Current testosterone treatment or treatment during the two years prior to study entry
• Current growth hormone treatment or treatment during the three years prior to study entry
• Use of other prescription or over-the-counter androgens (androstenedione, DHEA), estrogens, or antiandrogens (spironolactone, ketoconazole)
• Diseases that could influence bone, such as hyperparathyroidism
• Medications that could influence bone, such as anticonvulsants or glucocorticoids (prednisone greater than 20 mg/day for longer than 2 weeks/year). Calcium and over-the-counter vitamin D supplements are allowed.
• Cancer that could limit life expectancy to fewer than 5 years
• Neuromuscular disease or history of stroke with residual neurological defect
• Severe or uncontrolled psychiatric illness or dementia
• Noncancerous enlargement of the prostate gland (American Urological Association symptom score greater than 21)
• Prostate cancer by history, prostate nodule on digital rectal exam (DRE), or prostate specific antigen (PSA) greater than 4
• Current alcohol or drug dependence
• Heart failure (New York class III or IV)
• Unstable angina
• Myocardial infarction within 3 months of study entry
• Liver disease (ALT greater than 3 x normal)
• Renal disease (serum creatinine greater than 2.5 mg/dl)
• Diabetes mellitus (glycosolated hemoglobin greater than 8.0%)
• Hypertension (systolic BP greater than 160 or diastolic BP greater than 100 mm Hg)
• Hematocrit greater than 48%
• Weight greater than 300 pounds
• Poor quality scan at baseline even when repeated
• Untreated, severe, obstructive sleep apnea (Epworth sleepiness score greater than 10)
• Unable to undergo an MRI because of a cardiac pacemaker or ferrometallic objects in the body

Where it is running

• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.